Longitudinal Optical Coherence Tomography Measurement of Retinal Ganglion Cell and Nerve Fiber Layer to Assess Benign Course in Multiple Sclerosis

A benign form of multiple sclerosis (BMS) is not easily diagnosed, but changes of the retinal ganglion cell layer-inner plexiform layer (GCL-IPL) and retinal nerve fiber layer (RNFL) may be sensitive to the disease. The aim of this study was to use optical coherence tomography (OCT) to investigate longitudinal changes of GCL-IPL and RNFL in BMS. Eighteen patients with BMS and 22 healthy control (HC) subjects were included, with a mean follow-up period of 32.1 months in BMS and 34.3 months in HC. Mean disease duration in BMS was 23.3 years, with 14 patients left untreated. Unilateral optic neuritis (ON) was found in eight patients. Non-ON eyes showed thinner GCL-IPL layer in the BMS group relative to HC (p < 0.001). The thinning rate of GCL-IPL in non-ON BMS, however, was −0.19 ± 0.15 µm/year vs. 0 ± 0.11 µm/year for HC (p = 0.573, age-adjusted). Thinning rate of RNFL in non-ON BMS was −0.2 ± 0.27 µm/year vs. −0.05 ± 0.3 µm/year for HC (p = 0.454, age adjusted). Conclusions: Thinning rate of the GCL-IPL and RNFL in BMS is similar to the healthy population but differs from the thinning rate in relapsing-remitting MS, presenting a non-invasive OCT-based criterion for assessing a benign course in multiple sclerosis.

[1]  N. Lagali,et al.  Retinal ganglion cell layer thickness and volume measured by OCT changes with age, sex, and axial length in a healthy population , 2022, BMC Ophthalmology.

[2]  P. Nucci,et al.  Optical coherence tomography as retinal imaging biomarker of neuroinflammation/neurodegeneration in systemic disorders in adults and children , 2022, Eye.

[3]  A. Al-Mujaini,et al.  Retinal nerve fiber layer thickness in multiple sclerosis with and without optic neuritis: a four-year follow-up study from Oman , 2021, BMC Ophthalmology.

[4]  P. Hartikainen,et al.  Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis. , 2021, Multiple sclerosis and related disorders.

[5]  F. Piehl,et al.  Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. , 2021, JAMA neurology.

[6]  R. Zawadzki,et al.  In vivo multimodal retinal imaging of disease-related pigmentary changes in retinal pigment epithelium , 2021, Scientific Reports.

[7]  A. Grzybowski,et al.  Spectral-Domain Optical Coherence Tomography Assessment in Treatment-Naïve Patients with Clinically Isolated Syndrome and Different Multiple Sclerosis Types: Findings and Relationship with the Disability Status , 2021, Journal of clinical medicine.

[8]  E. Celius,et al.  The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression , 2020, Journal of Neurology.

[9]  F. Paul,et al.  Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. , 2020, Multiple sclerosis and related disorders.

[10]  Myeong Jin Ju,et al.  Directional optical coherence tomography reveals melanin concentration-dependent scattering properties of retinal pigment epithelium , 2019, Journal of biomedical optics.

[11]  V. Tomassini,et al.  How common is truly benign MS in a UK population? , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[12]  F Zipp,et al.  ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis , 2018, European journal of neurology.

[13]  David H. Miller,et al.  ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis , 2018, Multiple sclerosis.

[14]  H. Amthauer,et al.  End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry , 2017, Transplantation.

[15]  Alexander Klistorner,et al.  Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis , 2017, The Lancet Neurology.

[16]  G. Nagels,et al.  Definition, prevalence and predictive factors of benign multiple sclerosis , 2017, eNeurologicalSci.

[17]  M. Freedman,et al.  Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study , 2017, Journal of Neurology.

[18]  M. Fredrikson,et al.  Benign Multiple Sclerosis is Associated with Reduced Thinning of the Retinal Nerve Fiber and Ganglion Cell Layers in Non-Optic-Neuritis Eyes , 2015, Journal of clinical neurology.

[19]  A. Al-Hawasi,et al.  Acute optic neuritis: retinal ganglion cell loss precedes retinal nerve fiber thinning , 2015, Neurological Sciences.

[20]  C. Vass,et al.  Retinal Blood Vessel Distribution Correlates With the Peripapillary Retinal Nerve Fiber Layer Thickness Profile as Measured With GDx VCC and ECC , 2015, Journal of glaucoma.

[21]  F. Lublin,et al.  New Multiple Sclerosis Phenotypic Classification , 2014, European Neurology.

[22]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[23]  S. Graham,et al.  Axonal loss in non–optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential , 2013, Neurology.

[24]  J. Correale,et al.  Benign Multiple Sclerosis: Does it exist? , 2012, Current Neurology and Neuroscience Reports.

[25]  P. Calabresi,et al.  Visual Pathway Axonal Loss in Benign Multiple Sclerosis: A Longitudinal Study , 2012, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[26]  Xiang-Run Huang,et al.  Reflectance decreases before thickness changes in the retinal nerve fiber layer in glaucomatous retinas. , 2011, Investigative ophthalmology & visual science.

[27]  U. Schmidt-Erfurth,et al.  RNFL thickness in MS‐associated acute optic neuritis using SD‐OCT: critical interpretation and limitations , 2011, Acta ophthalmologica.

[28]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[29]  J. Aarseth,et al.  Benign multiple sclerosis: a need for a consensus , 2010, Acta neurologica Scandinavica. Supplementum.

[30]  A Giorgio,et al.  Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis , 2009, Neurology.

[31]  J. De Keyser,et al.  Predictive value of clinical characteristics for ‘benign’ multiple sclerosis , 2007, European journal of neurology.

[32]  H. Tremlett,et al.  Longitudinal follow-up of “benign” multiple sclerosis at 20 years , 2007, Neurology.

[33]  R. Kardon,et al.  Quantifying axonal loss after optic neuritis with optical coherence tomography , 2006 .

[34]  K. Myhr,et al.  Benign multiple sclerosis , 2006, Acta neurologica Scandinavica. Supplementum.

[35]  John Noseworthy,et al.  Clinical implications of benign multiple sclerosis: A 20‐year population‐based follow‐up study , 2004, Annals of neurology.

[36]  F Pierelli,et al.  Correlation between morphological and functional retinal impairment in multiple sclerosis patients. , 1999, Investigative ophthalmology & visual science.

[37]  G V McDonnell,et al.  Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors , 1999, Journal of neurology, neurosurgery, and psychiatry.

[38]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[39]  F. Ikuta,et al.  Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States , 1976, Neurology.